Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Prince

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
The Biochemical Journal|October 1, 2013
Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscleMelissa E Smith, Trevor S Tippetts, Eric S Brassfield, et al.
Clinical Immunology (Orlando, Fla.)|May 11, 2024
A novel IKZF1 variant in a family with autosomal dominant CVID: A case for expanding exon coverage in inborn errors of immunityIvana Stojkic, Benjamin T Prince, Hye Sun Kuehn, et al.
Blood Cancer Journal|September 10, 2013
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapyL Qin, B D Smith, H-L Tsai, et al.
Diabetology & Metabolic Syndrome|November 9, 2012
AICAR inhibits ceramide biosynthesis in skeletal muscleKatherine A Erickson, Melissa E Smith, Tamil S Anthonymuthu, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
The Journal of Heredity|November 29, 2015
Phylogeography, Genetic Diversity, and Management Units of Hawksbill Turtles in the Indo-PacificSarah M Vargas, Michael P Jensen, Simon Y W Ho, et al.
Oncotarget|February 8, 2019
Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic driftMonique M P Speirs, Adam C Swensen, Tsz Y Chan, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
The Biochemical Journal|October 1, 2013
Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscleMelissa E Smith, Trevor S Tippetts, Eric S Brassfield, et al.
Clinical Immunology (Orlando, Fla.)|May 11, 2024
A novel IKZF1 variant in a family with autosomal dominant CVID: A case for expanding exon coverage in inborn errors of immunityIvana Stojkic, Benjamin T Prince, Hye Sun Kuehn, et al.
Blood Cancer Journal|September 10, 2013
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapyL Qin, B D Smith, H-L Tsai, et al.
Diabetology & Metabolic Syndrome|November 9, 2012
AICAR inhibits ceramide biosynthesis in skeletal muscleKatherine A Erickson, Melissa E Smith, Tamil S Anthonymuthu, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
The Journal of Heredity|November 29, 2015
Phylogeography, Genetic Diversity, and Management Units of Hawksbill Turtles in the Indo-PacificSarah M Vargas, Michael P Jensen, Simon Y W Ho, et al.
Oncotarget|February 8, 2019
Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic driftMonique M P Speirs, Adam C Swensen, Tsz Y Chan, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Pageof 17